Free Trial

Galmed Pharmaceuticals (GLMD) Competitors

Galmed Pharmaceuticals logo
$2.01 +0.18 (+10.07%)
As of 01:59 PM Eastern

GLMD vs. TRIB, ATHA, BGXX, BCDA, EQ, SNSE, LPTX, BTAI, XFOR, and PHXM

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Trinity Biotech (TRIB), Athira Pharma (ATHA), Bright Green (BGXX), BioCardia (BCDA), Equillium (EQ), Sensei Biotherapeutics (SNSE), Leap Therapeutics (LPTX), BioXcel Therapeutics (BTAI), X4 Pharmaceuticals (XFOR), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

Galmed Pharmaceuticals vs. Its Competitors

Trinity Biotech (NASDAQ:TRIB) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -51.64%. Trinity Biotech's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-51.64% N/A -27.43%
Galmed Pharmaceuticals N/A -32.21%-28.59%

In the previous week, Trinity Biotech had 1 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Galmed Pharmaceuticals. Trinity Biotech's average media sentiment score of 0.00 equaled Galmed Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Trinity Biotech Neutral
Galmed Pharmaceuticals Neutral

Galmed Pharmaceuticals has lower revenue, but higher earnings than Trinity Biotech. Trinity Biotech is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$61.56M0.22-$31.79M-$2.82-0.26
Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.12

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Galmed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Trinity Biotech has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Summary

Trinity Biotech beats Galmed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLMD vs. The Competition

MetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.33M$2.37B$5.46B$8.93B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-0.128.9127.0720.17
Price / SalesN/A508.47381.5293.95
Price / CashN/A21.7726.2128.59
Price / Book0.204.528.015.59
Net Income-$7.52M$31.26M$3.17B$248.41M
7 Day Performance13.49%6.13%3.53%6.17%
1 Month Performance33.78%5.69%2.73%7.83%
1 Year Performance-45.17%1.32%34.10%21.03%

Galmed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLMD
Galmed Pharmaceuticals
N/A$2.02
+10.4%
N/A-50.9%$3.33MN/A-0.1220
TRIB
Trinity Biotech
0.51 of 5 stars
$0.65
-0.3%
N/A-64.0%$11.77M$61.56M-0.23480Gap Down
ATHA
Athira Pharma
2.4904 of 5 stars
$0.30
+2.4%
$11.25
+3,625.2%
-87.1%$11.52MN/A-0.1540
BGXX
Bright Green
N/AN/AN/AN/A$11.47MN/A-1.002Gap Down
BCDA
BioCardia
3.9595 of 5 stars
$1.95
-9.3%
$25.00
+1,182.1%
-29.3%$11.13M$60K-0.8440Positive News
EQ
Equillium
1.8276 of 5 stars
$0.32
+1.7%
$3.00
+851.8%
-53.1%$11.07M$41.10M-0.8140
SNSE
Sensei Biotherapeutics
4.169 of 5 stars
$8.58
-1.2%
$90.00
+949.0%
-26.5%$10.94MN/A-0.3740
LPTX
Leap Therapeutics
1.4003 of 5 stars
$0.30
+13.5%
$3.38
+1,036.7%
-85.8%$10.84MN/A-0.1740
BTAI
BioXcel Therapeutics
4.5208 of 5 stars
$1.81
+2.3%
$42.60
+2,253.6%
-88.7%$10.72M$2.27M-0.1390Positive News
XFOR
X4 Pharmaceuticals
4.6438 of 5 stars
$1.90
+3.8%
$72.33
+3,707.0%
-89.8%$10.59M$2.56M0.8980Gap Up
High Trading Volume
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049

Related Companies and Tools


This page (NASDAQ:GLMD) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners